中国生物技术：下一代免疫肿瘤（IO）领域的机遇；管线更新及目标价变动-China Biotechnology_ Opportunities in Next-generation IO Space; Pipeline Updates and TP Changes
2025-07-30 02:33
Opportunities in Next-generation IO Space; Pipeline Updates and TP Changes CITI'S TAKE V i e w p o i n t | 25 Jul 2025 09:58:42 ET │ 28 pages China Biotechnology Next-generation immuno-oncology (IO) therapeutics, such as bi/trispecific PD-1/VEGF, PD-1/IL-2, PD-1/VEGF/CTLA4, have the potential to reshape the landscape of cancer IO treatment. We think investors are keen to value next-generation IO candidates in company pipelines – we summarize our work in Figure 1, while our framework factors in market share ...